No Heading
Purpose.
Multidrug-resistance–associated protein 2 (Mrp2) shows a broad substrate specificity toward amphiphilic organic anions. This study identified key functional groups of ligand molecules for binding to rat Mrp2, determined their relative locations, and examined substrate specificity through receptor mapping using three-dimensional (3D) quantitative structure-activity relationship (3D-QSAR) analysis.
Methods.
Ligand-binding conformations were estimated using conformational analysis (CAMDAS) and molecular superposition (SUPERPOSE) methods to clarify the substrate specificity of rat Mrp2 in relation to 3D ligand structures.
Results.
Two types of binding conformations of ligands for rat Mrp2 were identified. 3D-QSAR comparative molecular-field analysis (CoMFA) revealed a statistically significant model for one type, in which the steric, electrostatic, and log P contributions to the binding affinity for rat Mrp2 were 63.0%, 33.4%, and 3.6%, respectively (n = 16, q2 = 0.59, n = 3, r2 = 0.99, and s = 0.08).
Conclusions.
The 3D pharmacophore of ligands for rat Mrp2, and the ligand-binding region of rat Mrp2, were estimated. Ligand recognition of rat Mrp2 is achieved through interactions in two hydrophobic and two electrostatically positive sites (primary binding sites). The broad substrate specificity of rat Mrp2 might result from the combination of secondary (two electrostatically positive and two electrostatically negative sites) and primary binding sites.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ABC:
-
ATP-binding cassette
- CAMDAS:
-
Conformational Analyzer with Molecular Dynamics and Sampling
- C log P:
-
calculated log P
- CMVs:
-
canalicular membrane vesicles
- CoMFA:
-
comparative molecular-field analysis
- EHBR:
-
Eisai hyperbilirubinemic rat
- MD:
-
molecular dynamics
- Mrp2:
-
multidrug-resistance–associated protein 2
- PLS:
-
partial least squares
- QSAR:
-
quantitative structure-activity relationship
- rmsd:
-
root-mean-square deviation
- SD:
-
Sprague-Dawley
References
1. O. R. P. Elferink, D. K. Meijer, F. Kuipers, P. L. Jansen, A. K. Groen, and G. M. Groothuis. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1241:215–268 (1995).
2. M. Yamazaki, H. Suzuki, and Y. Sugiyama. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 13:497–513 (1996).
3. D. Keppler and J. Konig. Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the Mrp2 (cMRP/cMOAT) gene in liver. FASEB J. 11:509–516 (1997).
4. K. Ito, H. Suzuki, T. Hirohashi, K. Kume, T. Shimizu, and Y. Sugiyama. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am. J. Physiol. 272:G16–G22 (1997).
5. C. C. Paulusma, P. J. Bosma, G. J. Zaman, C. T. Bakker, M. Otter, G. L. Scheffer, R. J. Scheper, P. Borst, and O. R. P. Elferink. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126–1128 (1996).
6. K. Sathirakul, H. Suzuki, K. Yasuda, M. Hanano, O. Tagaya, T. Horie, and Y. Sugiyama. Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. J. Pharmacol. Exp. Ther. 265:1301–1312 (1993).
7. K. Sathirakul, H. Suzuki, T. Yamada, M. Hanano, and Y. Sugiyama. Multiple transport systems for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther. 268:65–73 (1994).
8. M. Yamazaki, S. Akiyama, K. Ni’inuma, R. Nishigaki, and Y. Sugiyama. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab. Dispos. 25:1123–1129 (1997).
9. H. Ishizuka, K. Konno, H. Naganuma, K. Sasahara, Y. Kawahara, K. Niinuma, H. Suzuki, and Y. Sugiyama. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J. Pharmacol. Exp. Ther. 280:1304–1311 (1997).
10. H. C. Shin, Y. Kato, T. Yamada, K. Niinuma, A. Hisaka, and Y. Sugiyama. Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. Am. J. Physiol. 272:G979–G986 (1997).
11. T. Ishikawa, M. Muller, C. Klunemann, T. Schaub, and D. Keppler. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J. Biol. Chem. 265:19279–19286 (1990).
12. K. Kobayashi, Y. Sogame, H. Hara, and K. Hayashi. Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. J. Biol. Chem. 265:7737–7741 (1990).
13. T. Nishida, Z. Gatmaitan, J. Roy-Chowdhry, and I. M. Arias. Two distinct mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane vesicles. Demonstration of defective ATP-dependent transport in rats (TR-) with inherited conjugated hyperbilirubinemia. J. Clin. Invest. 90:2130–2135 (1992).
14. O. Takenaka, T. Horie, K. Kobayashi, H. Suzuki, and Y. Sugiyama. Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharm. Res. 12:1746– 1755 (1995).
15. M. Trauner, M. Arrese, C. J. Soroka, M. Ananthanarayanan, T. A. Koeppel, S. F. Schlosser, F. J. Suchy, D. Keppler, and J. L. Boyer. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113:255–264 (1997).
16. X. Y. Chu, Y. Kato, and Y. Sugiyama. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 57:1934–1938 (1997).
17. H. Suzuki and Y. Sugiyama. Role of transporters in the detoxification of xenobiotics: recent advances in the study of cMOAT/MRP. Tanpakushitsu Kakusan Koso 42:1273–1284 (1997).
18. H. Tsujishita and S. Hirono. CAMDAS: an automated conformational analysis system using molecular dynamics. J. Comput. Aided Mol. Des. 11:305–315 (1997).
19. K. Iwase and S. Hirono. Estimation of active conformations of drugs by a new molecular superposing procedure. J. Comput. Aided Mol. Des. 13:499–512 (1999).
20. R. D. Cramer, D. E. Patterson, and J. D. Bunce. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110:5959–5967 (1988).
21. N. L. Allinger. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J. Am. Chem. Soc. 99:8127–8134 (1977).
22. H. Suzuki and Y. Sugiyama. Transporters for bile acids and organic anions. Pharm. Biotechnol. 12:387–439 (1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hirono, S., Nakagome, I., Imai, R. et al. Estimation of the Three-Dimensional Pharmacophore of Ligands for Rat Multidrug-Resistance–Associated Protein 2 Using Ligand-Based Drug Design Techniques. Pharm Res 22, 260–269 (2005). https://doi.org/10.1007/s01869-005-1869-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s01869-005-1869-8